Descovy non-inferior to Truvada for HIV prevention

Gilead reported on March 6 that once-daily Descovy emtricitabine/tenofovir alafenamide met the primary endpoint of non-inferiority to once-daily Truvada emtricitabine/tenofovir in the Phase III DISCOVER trial to prevent HIV infection. Gilead Sciences Inc. (NASDAQ:GILD) said the data will support supplemental regulatory applications for Descovy as pre-exposure prophylaxis (PrEP).

Gilead's Truvada is the only FDA-approved PrEP therapy...